The objective of this study was to investigate the catalytic activity of basic aminopeptidase (APB) and its association with periarticular edema and circulating tumor necrosis factor (TNF)-alpha and type II collagen (CII) antibodies (AACII) in a rat model of rheumatoid arthritis (RA) induced by CII (CIA). Edema does not occur in part of CII-treated, even when AACII is higher than in control. TNF-alpha is detectable only in edematous CII-treated. APB in synovial membrane is predominantly a membrane-bound activity also present in soluble form and with higher activity in edematous than in non-edematous CII-treated or control. Synovial fluid and blood plasma have lower APB in non-edematous than in edematous CII-treated or control. In peripheral blood mononuclear cells (PBMCs) the highest levels of APB are found in soluble form in control and in membranebound form in non-edematous CII-treated. CII treatment distinguishes two categories of rats: one with arthritic edema, high AACII, detectable TNF-alpha, high soluble and membrane-bound APB in synovial membrane and low APB in the soluble fraction of PBMCs, and another without edema and with high AACII, undetectable TNF-alpha, low APB in the synovial fluid and blood plasma and high APB in the membranebound fraction of PBMCs. Data suggest that APB and CIA are strongly related.
Introduction
Rheumatoid arthritis (RA) is an inflammatory, chronic, systemic and autoimmune disease [1, 2] of unknown etiology [1] [2] [3] [4] that affects about 1% of the world's population [1, 2, 5] . It is associated with increased mortality and significant comorbidities and other factors that can specifically affect a patient's quality of life [6, 7] . The prominent characteristic of RA is a symmetrical peripheral polyarthritis with bone erosions, mainly of cartilage, and resultant deformity and joint destruction [8] . This process is associated with inflammatory hyperplasia of the synovial membrane, also known as pannus [9] , and pathological neovascularization, which occur after the infiltration of inflammatory cells into the synovial membranes [10] , as well as an immune response against cartilage components, among them the type II collagen (CII) has been thought to be the most usual [8] . Tumor necrosis factor (TNF)-alpha has also been found in high concentrations in the serum and synovial fluid of RA patients [1, 10] .
The genetic predisposition linked to human leukocyte antigen system has been estimated to contribute with about 50% or less for the development of disease [11] . Thus, several epigenetic factors appear to be involved in the onset of RA, such as DNA methylation, alternative splicing, micro RNAs and histone modifications [11] . Moreover, factors such as infections, smoking, pregnancy, sex hormones and others may lead to autoimmunity [4] . CII is considered the primary antigen in RA, since it is the main constituent of cartilage [2] and because antibodies anti-CII (AACII) have been detected in synovial fluid [5, 12] , cartilage and B cells present in the synovial membrane of arthritic patients [12] . Furthermore, manifestations of RA have close similarity with those of the experimental model of CII-induced arthritis (CIA), that are: synovitis, progressive pannus formation, marginal erosion of bone and cartilage destruction [5, 12, 13] . The transfer of AACII is also able to induce RA, because these antibodies bind to normal cartilage and activate the complement system [5] . In the CIA model, symptoms of RA begin about 21 days after the injection of CII [13] . According to Stuart et al. [9] , the initial lesion observed in this experimental model of RA is fibrin deposition in the synovial membrane 5 days after immunization. On the 12th day there is an intense deposition of fibrin and tissue hyperplasia. On the 19th day the infiltration of mononuclear and polymorphonuclear cells begins. Inflammation occurs so rapidly that the destruction of cartilage and the marginal erosion of the bone occur in a few days [9] .
Regarding the evidences that altered matrix metalloproteinase and other proteins implicated in matrix degradation, cell activation, inflammation and bone collagen degradation products accompany early rheumatoid and osteoarthritis development and can precede the canonical diagnostic detection by several years [14, 15] , as well as that CD13, an aminopeptidase type enzyme, was histologically expressed strongly in RA synovial tissue lining cells [16] , it can be hypothesized that changes of other aminopeptidase hydrolytic activities, such as the basic aminopeptidase (APB) activity, could be important in RA, mainly because APB activity was reported to be increased in the soluble fraction of elicited macrophages [17] and because kallidin [18] , leukotriene(LT)-A4 [19, 20] and angiotensin (Ang) III [21] , three of the known natural substrates susceptible to hydrolysis by isozymes with APB activity, have recognized actions in regulating angiogenesis [22] and inflammation [23] .
To prospect new markers and contribute to elucidate the etiology of RA, this study aims to assess changes in the APB activity of blood plasma, synovial fluid and soluble (SF) and solubilized membranebound (MF) fractions from the synovial membrane of the knee and from peripheral blood mononuclear cells (PBMCs), associating this enzyme activity with hind paw edema and with the AACII titer in blood plasma and TNF-alpha levels in blood serum of control and CIItreated rats.
Materials and methods

Animals, treatments and samples
Adult male Wistar rats, weighing 150-160 g, provided by the Animal Facility of the Instituto Butantan, were maintained in polyethylene cages (inside length × width × height = 56 × 35 × 19 cm) with food and tap water ad libitum, in a container with controlled temperature of 25°C, relative humidity of 65.3 ± 0.9% and 12 h:12 h photoperiod light:dark (lights on at 6:00 am). The animals and research protocols used in this study are in agreement with the COBEA (Brazilian College of Animal Experimentation) and were approved by the Ethics Committee of the Instituto Butantan (682/09).
The animals were anesthetized with a solution of ketamine (Ketamine, Syntec, Cotia, São Paulo, Brazil) (3.75%) and xylazine (Calmiun, Agener Union, Planalto Paulista, São Paulo, Brazil) (0.5%) at a dose of 0.2 mL/100 g body weight, via intraperitoneal, and then subjected to induction of arthritis by administration of CII from chicken (Sigma, St. Louis, MO, USA) dissolved in 0.01 M acetic acid and emulsified in an equal volume of Freund's incomplete adjuvant (Sigma, St. Louis, MO, USA) (prepared at 4°C just before use), via a single intradermal dose of 0.4 mg/0.2 mL/animal, into the proximal one-third of the tail (induced animals), or with 0.9% saline at the same scheme of administration (sham induction). On day 41 after treatment, the animals were anesthetized using the same scheme specified above and the thickness of the hind paws were measured in order to evaluate edema. Based on this measurement the following experimental groups were formed: Control (all animals submitted to sham induction); Arthritic (induced animals with hind paw thickness N7 mm); Resistant (induced animals with hind paw thickness similar to control). Thus, blood was withdrawn from the left ventricle with heparinized and not heparinized syringes in order to obtain plasma and serum, respectively. Heparinized blood was centrifuged (at 200× g for 10 min at room temperature) to separate plasma (supernatant) from the pellet containing PBMCs and other blood cells. The non-heparinized blood was left at room temperature for 10 min and then centrifuged under the same conditions to obtain the serum. The synovial fluid and synovial membrane were subsequently removed from both knees of each animal. The withdrawal of synovial fluid and synovial membrane was performed as follows: 200 μL of 0.9% NaCl was injected intraarticularly into each knee and aspirated with a syringe and, after such washing, the synovial membrane was excised together with the connective tissue of the joint capsule.
Separation of PBMCs
According to the method of Maldonado and Curi [24] with modifications as follow: the pellet resulting from the obtainment of blood plasma was reconstituted to the original volume with 0.9% NaCl and then carefully layered on equal volume of Percoll (ρ = 1.077 mg/mL) (GE-Healthcare) and subsequently centrifuged (200× g for 20 min at room temperature). The layer containing the PBMCs was then removed from the tube and washed twice with 0.9% NaCl (1:3 v/v diluted blood cells) and centrifuged again at the same conditions to discard the supernatant.
Cell counting and viability
PBMCs were resuspended in 0.5 mL of 0.9% NaCl. The total number of PBMCs was assessed in 20 μL aliquots of this suspension diluted with Turk's fluid (1:20, v/v). The cell viability was assessed using 40 μL aliquots of this suspension diluted in equal volume of Trypan. Cell counting was performed in a Neubauer chamber under optical microscopy.
Evaluation of the canonical signs of RA
Paw edema
Hind paw swelling was quantified by macroscopic measurement of the dorsal-plantar thickness of the hind paws in the region of the metatarsus with a paquimeter (Mitutoyo, Aurora, IL, USA). Both paws were measured and the average thickness was calculated for each animal.
Molecular markers
AACII was measured in blood plasma and TNF-alpha was measured in blood serum with Enzyme-Linked ImmunoSorbent Assay (ELISA) kits purchased from Chondrex (Redmond, WA, USA) and Biosource (Carlsbad, CA, USA), respectively, according to the manufacturer's recommendations.
Obtaining SF and MF from the synovial membranes and PBMCs
The synovial membranes from both knees of each animal were homogenized in 10 mM Tris-HCl buffer, pH 7.4 (0.1 g tissue/3.0 mL) for 3 min at 15,000 rpm (homogenizer Polytron-Aggregate, Kinematica, Lucerne, Switzerland). PBMCs, resuspended in 0.9% NaCl, were sonicated in 10 mM Tris-HCl, pH 7.4 (3.0 × 10 6 cells/mL), for 10 s at an amplitude level of 40 microm at a constant frequency of 20 KHz. These samples were then ultracentrifuged at 100,000× g for 35 min (ultracentrifuge Hitachi model CP60E). The resulting supernatants correspond to SF. The resulting pellets were washed twice with the same buffer and ultracentrifuged at 100,000× g for 35 min, to assure the complete removal of SF. Subsequently, the pellet was homogenized for 3 min at 800 rpm (homogenizer Tecnal TE 099, Tecnal, Piracicaba, SP, Brazil) with the same volume of the same buffer plus Triton X-100 (0.1%) and ultracentrifuged again (100,000× g for 35 min). The resulting supernatants correspond to MF. All procedures were carried out at 4°C. As a marker for the fractionation procedure, lactate dehydrogenase (LDH) activity was determined, photometrically, at 340 nm, in SF and MF, as previously described [25] . Briefly, samples of 3 μL of SF and MF, in triplicates, were incubated with 297 μL of 100 mM phosphate buffer, pH 7.4, containing 200 mM NaCl and 1.6 mM sodium pyruvate solution (Sigma, St. Louis, MO, USA) and 0.2 mM nicotinamide adenine dinucleotide, reduced form (NADH) disodium salt (Sigma, St. Louis, MO, USA). Two measurements of absorbance at 340 nm were performed: the first at zero time and the second after 10 min of incubation at 37°C. Values of LDH activity (mM oxidized NADH min −1 mg protein
) were obtained by subtracting the values of the second from that of the first reading, and extrapolated by comparison with a standard curve of NADH.
Total protein
Total protein was measured photometrically (Bio-Tek Power Wave XR spectrophotometer, Bio-Tek, Winooski, VT, USA), at 630 nm, in triplicates of 40 μL of synovial fluid, plasma (diluted 500-fold) and SF (diluted 10-fold) and MF (diluted 2-fold) from the synovial membrane and PBMCs by the method of Bradford [26] , using a BioRad protein assay reagent (Hercules, CA, USA). Protein contents were extrapolated by comparison with standard curves of bovine serum albumin (BSA) in the same diluent.
APB activity
As previously described by Zambotti-Villela et al. [27] , using 25 μL individual samples of blood plasma (205 to 450 μg protein), and synovial fluid (12 to 49 μg protein) and the SF (2.8 to 20 μg protein) and MF (2.6 to 15 μg protein) from the synovial membrane, and 50 μL and 100 μL individual samples respectively of SF (22 to 72 μg protein) and MF (13 to 44 μg protein) from PBMCs, on the basis of the amount of β-naphthylamine (Sigma, St. Louis, MO, USA) released as a result of the enzyme activity of samples incubated at 37°C for 30 min in 96-well flat bottom microplates (Corning Inc., NY, USA) with prewarmed substrate solution of 0.5 mM L-arginine β-naphthylamide (Sigma, St. Louis, MO, USA) to a final volume of 300 μL in 0.05 M phosphate buffer, pH 6.5, with 150 mM NaCl, 0.02 mM puromycin (Sigma, St. Louis, MO, USA) and 0.1 mg BSA/mL. β-Naphthylamine was estimated fluorometrically using the Bio-Tek FL600FA Microplate Fluorescence/ Absorbance Reader, at 460/40 nm emission wavelength and 360/ 40 nm excitation wavelength. The value of incubates at zero time (blank) was subtracted and the relative fluorescence was converted to picomoles of β-naphthylamine by comparison with a correspondent standard curve. APB activity was expressed as picomoles of hydrolyzed substrate min −1 mg protein −1 .
Data analysis
Data are shown as mean ± standard error of the mean (SEM) and were analyzed statistically using the GraphPad Instat™ software package. Regression analyses were performed to obtain standard curves of protein, NADH and β-naphthylamine. Student's t-test was performed to compare values of LDH between SF and MF. To compare values among the control, arthritic and resistant groups one-way analysis of variance (ANOVA) was performed, followed by Student-Newman-Keuls multiple comparisons test when differences were detected. In all the calculations a minimum critical level of P b 0.05 was set.
Results
Induction of arthritis
Development of paw edema
About 40% of the animals submitted to CII treatment did not develop paw swelling. Fig. 1 shows the swelling developed by animals "sensitive" to the treatment with CII relatively to the absence of swelling in control (sham induction) and animals "insensitive" to the treatment with CII. Table 1 shows that AACII titer in blood plasma of the CII-treated animals that developed or not the edema was higher than that of control. Table 1 also shows that TNF-alpha levels in blood serum did not differ between control and CII-treated animals without edema, but these levels were higher in blood serum of CII-treated animals with edema than in control.
Molecular markers
Efficiency of synovial membrane fractionation
In all groups under study the LDH activity of the synovial membrane was detected only in the SF (mean ± SEM, control group, n = 8; 0.81 ± 0.15, P b 0.0001, unpaired, two-side Student's t test); in the MF this activity was null (control group, n = 8). Qualitatively similar results were obtained in the SF and MF from PBMCs of all groups (data not shown). Fig. 2 shows that APB activity is strongly expressed in the MF from the synovial membrane of all groups under study. APB activity in the SF and MF from the synovial membrane was higher in CIItreated animals with swollen paws (arthritic) than in control or CIItreated that did not develop paw swelling (resistant). Resistant and control animals had similar APB activity in the SF and MF from the Table 1 Titer of antibodies anti-type II collagen (AAC-II) and levels of tumor necrosis factor (TNF)-alpha in sham induced (control), CIA-treated that developed hind paw edema (arthritic) and CIA-treated rats that did not develop hind paw edema (resistant).
APB activity
Animals
Blood plasma AAC-II Blood serum TNF-alpha synovial membrane. Fig. 2 also shows that APB activity in synovial fluid and blood plasma was lower in resistant than in control or arthritic animals, while arthritic animals and control animals had similar APB activity. Fig. 3 shows that APB activity in the SF from PBMCs of control was higher than in arthritic or resistant animals. On the other hand, APB activity in the MF from PBMCs of resistant was higher than in control or arthritic animals. 
Discussion
Edema, AACII and TNF-alpha
CIA in rats or mice is the most commonly used animal model to evaluate approved and pending therapies or to investigate the pathogenesis of RA. Based on the degree of hind paw swelling (edema) formed 41 days after the treatment with CII emulsified in Freund's incomplete adjuvant, the present study characterized the existence of CII-treated animals susceptible or resistant to the induction of RA. Edema of the paws is the main feature of RA induced by CII and is commonly used as a parameter for evaluating the presence of RA [13, 28] . The incidence of RA (edema) was 44% and 100% in the methods of CIA used respectively by Trentham et al. [13] and Cuzzocrea et al. [28] , while in the present study was about 60%. TNF-alpha has been considered a major proinflammatory cytokine in RA [1, 10] , and the differences detected here in TNF-alpha levels in serum among arthritic, resistant and control animals agree with this rule. Both CII-treated with edema and without edema showed a high AACII titer, which would be expected only in immunized animals with intense edematous response [29] . However, altered AACII titer occurs in several diseases [30] and as evidenced in the present study it could not be considered a differential parameter for RA. The present study describes for the first time that a considerable proportion of CIItreated animals with high AACII titer does not develop edema, a finding that reinforces the multifactorial feature of RA triggering and the hypothesis that CII, as a large molecule, contains different epitopes with different degrees of immunoreactivity for different antibodies, and these antibodies for CII could be pathogenic and nonpathogenic [30] . The distinction between these possible types of antibodies would have great impact on the diagnosis and treatment of RA.
APB and the susceptibility and resistance to develop RA in the CIA model
Some factors can interfere with the successful onset of macroscopic signs of RA in CIA models, such as the denaturation of collagen during dissolution and differences in animal lineages used [31, 32] . Obviously, the crucial question of medical interest is not related to the discrimination of exogenous factors that can determine the efficiency of the methods of induction, but the identification of possible endogenous determinants of resistance of certain animals to develop RA induced by these methods. On the other hand, as pointed out by Hegen et al. [33] the questions of which animal model is most predictive of therapeutic efficacy or has more pathophysiological features of human RA commonly arise in data evaluation, and obviously the study in several models can be more predictive than the data from either model alone. In this sense, the model used in the present study is very interesting because it showed that APB activity can be an attractive diagnostic tool for the determination of the outcome of RA, and that this catalytic activity can be also used to estimate the susceptibility to develop RA.
Possible mechanisms generating the altered APB activity in the CIA model
APB hydrolytic activity is known to be exhibited by the proteins EC 3.4.11.6 and leukotriene A4-hydrolase (LTA4H) (EC 3.3.2.6). The present study focuses only on APB catalytic activity without the aim to identify the protein(s) responsible for this activity. It is known that EC 3.4.11.6 preferentially hydrolyzes basic residues (arginine and lysine) of the N-terminal of several peptides [19, 34] , being widely distributed in various tissues as a monomeric protein with molecular weight of 72,300 kDa [19, 34] , comprising 649 amino acid residues, showing 33% identity and 48% similarity with EC 3.3.2.6, and also exhibiting the catalytic activity of LTA4H [19, 20] . In most cells studied, the protein EC 3.4.11.6 seems to be predominantly cytosolic and secreted, but it has also been found to be associated with the membrane [18, 19] and the Golgi apparatus, possibly transiting from the endoplasmic reticulum to the Golgi complex [18] . However, there is no description of transmembrane domains in its structure, and one hypothesis is that it interacts with a membrane receptor [19] . Intracellularly, the protein EC 3.4.11.6 could be involved in antigen processing, because it is present in the proteasome [35] . The peptides generated by proteasome degradation are incorporated into the endoplasmic reticulum where they bind to MHC II [35] . Moreover, many peptides in the endoplasmic reticulum undergo cleavage of N-terminal residue [35] and the protein EC 3.4.11.6 could also act in that compartment, helping antigenic processing. On the other hand, the membraneassociated APB could act on extracellular angiogenic peptides such as kallidin [18] and Ang-III [21] . Pannus formation, in both RA and CIA, is angiogenesis-dependent and it has been increasingly recognized that peptides are part of a pathogenic mechanism that contributes to autoimmune inflammation in RA [36] .
In the present study, the highest expression of APB activity was found in the membrane-bound fraction from the synovial membrane, and this activity was also present in the membrane-bound fraction from PBMCs after a successful fractionation of soluble and membranebound fractions from these samples, as demonstrated by LDH activity. Thus, the present study is the first one to analyze APB activity in these separate fractions from the synovial membrane and PBMCs. A question arised from this data is whether soluble APB activity in synovial fluid and blood plasma is derived from synovial membrane and/or PBMCs. For another aminopeptidase, the dipeptidyl peptidase IV, the mechanism of shedding from the cell surface to the plasma is thought to be caused by plasma enzymes [37] . This question and the pathophysiological significance of APB activity, not only in the membrane fraction but also in the soluble fraction from the synovial membrane, soluble and membrane fractions of PBMCs and in synovial fluid and blood plasma need further studies to be elucidated. For example, it is known that the APB activity of the protein EC 3.4.11.6 increases in the presence of physiological concentrations of chloride [34] . It is also known that changes in the levels of LTA4 and LTB4 (the product of the catalytic action of the proteins EC 3.3.2.6 and EC 3.4.11.6 on LTA4) generate changes in the APB activity of the protein EC 3.4.11.6 [15] , but it is unclear whether there is a mutual interference of peptide and eicosanoid substrates in each of the catalytic activities of the protein EC 3.4.11.6. Moreover, both of the catalytic activities of the protein EC 3.3.2.6, that are epoxide hydrolase on LTA4 [20, 38, 39] and peptide hydrolase on L-arginine β-naphthylamide and analogs [38] [39] [40] , are inhibited by divalent cations and stimulated by monovalent anions, including chloride [34, 40, 41] , as similarly occur with the protein EC 3.4.11.6 [34] , thus complicating the distinction between these two proteins. Furthermore, the protein EC 3.3.2.6 appears to suffer suicidal inactivation when it is exposed to its lipid substrate LTA4 [34] .
Present significance of altered APB activity in the CIA model
Although the present study does not help to distinguish whether one or both proteins are responsible for APB activity, in an important area of controversy it suggested that the balance of intracellular APB in PBMCs (activity in the soluble fraction of these cells) is crucial in the triggering of RA. Furthermore, the present study clearly demonstrated that the detection of increased levels of this catalytic activity in the soluble and membrane-bound fractions from the synovial membrane could help to the diagnosis of RA, while the detection of decreased levels of this catalytic activity in synovial fluid and blood plasma, as well as of increased levels in membrane-bound fractions from PBMCs is a feature of resistance to develop RA with potential prognostic implications.
Possible implications of altered APB activity in RA
The role of polymorphisms in disease susceptibility is becoming increasingly relevant for the perspective of current medical practice [42] . Could a high stability of membrane-bound APB in the PBMCs and the consequent reduction of its release in body fluids be an individual protective factor against RA? It seems an interesting question to be further investigated. Recently, the neutrophil chemoattractant ProGly-Pro (PGP), a biomarker for chronic obstructive pulmonary disease, was identified as one of the physiological substrates of the aminopeptidase activity of LTA4H [43] . In acute neutrophil driven inflammation, PGP was degraded by aminopeptidase activity, which facilitated the resolution of inflammation, but in chronic obstructive pulmonary disease, the inhibition of this aminopeptidase activity could lead to the accumulation of PGP and neutrophils [43] .
Concluding remarks
The treatment with CII emulsified in Freund's incomplete adjuvant leads the rats to develop arthritic edema, high AACII, detectable TNFalpha, high APB activity in the soluble and membrane-bound fractions from the synovial membrane and low APB in the soluble fraction of PBMCs or, on the other hand, absence of edema, high AACII, undetectable TNF-alpha, low APB in the synovial fluid and blood plasma and high APB in the membrane-bound fraction of PBMCs. Data suggest that APB represents potentially a new marker of diagnosis (in synovial membrane and soluble fraction from PBMCs) and/or prognosis (in synovial fluid, blood plasma and membrane-bound fraction from PBMCs) of RA. Given these data we believe that APB activity monitoring in RA patients at risk for or with existing joint pain and/or inflammation could be a cheap, simple and effective means to harness the clinical potential of this parameter for diagnosis and prognosis of RA. These data also suggest that the inhibition of APB activity in extracellular fluids such as synovial fluid and blood plasma needs to be investigated as a potential strategy for therapeutic intervention in RA.
